Asia Pacific Breast Cancer Therapeutics Market Report

Asia Pacific Breast Cancer Therapeutics Market Size

The Asia Pacific Breast Cancer Therapeutics Market size was valued at USD 5.88 billion in 2025 and is anticipated to reach USD 6.7 billion in 2026 from USD 19.07 billion by 2034, growing at a CAGR of 13.97% during the forecast period from 2026 to 2034.

Breast cancer therapeutics are pharmacological and biological interventions designed to target malignant cells in breast tissue, including hormone therapies, targeted biologics, chemotherapy, and immunotherapies. According to the World Health Organization, breast cancer has become the most commonly diagnosed cancer among women in urban centers across the region, surpassing cervical cancer in countries such as Australia, Japan, and South Korea. As per the International Agency for Research on Cancer, an estimated 1.1 million new cases of breast cancer were diagnosed globally in 2023, with over 38% originating from the Asia Pacific region. Lifestyle transitions, including delayed childbearing, reduced breastfeeding, and increased sedentary behavior, are contributing to shifting epidemiological patterns. In India, the National Centre for Disease Informatics and Research reports that breast cancer now accounts for nearly 28% of all cancers in women, with urban incidence rates doubling over the past two decades. Similarly, in China, the National Cancer Center indicates that urban women face a 1.5 times higher risk of breast cancer than their rural counterparts, driven by environmental and metabolic factors.

MARKET DRIVERS

Rising Incidence of Hormone Receptor-Positive Breast Cancer Subtypes

The escalating prevalence of hormone receptor-positive (HR+) breast cancer rises the therapeutic demand for endocrine-based treatments such as aromatase inhibitors and selective estrogen receptor modulators, which is substantially fuelling the growth of the Asia Pacific Breast Cancer Therapeutics Market. HR+ tumors, which rely on estrogen for growth, constitute approximately 65–70% of all breast cancer cases in urban populations across the region, as reported by the Asian Oncology Summit 2023. In Japan, the National Cancer Center indicates that over 72% of newly diagnosed breast cancer cases are HR+, a figure that has increased from 58% in 2000 due to dietary shifts and hormonal influences. Similarly, in Australia, the Australian Institute of Health and Welfare notes that HR+ subtypes account for 75% of diagnoses, underpinning the widespread use of therapies like anastrozole and fulvestrant. Urbanization-related factors such as obesity, late menopause, and prolonged exposure to endogenous estrogen are amplifying this trend. In South Korea, the Korean Breast Cancer Society reports a 40% rise in HR+ cases between 2010 and 2022, coinciding with increased consumption of processed foods and reduced physical activity. These epidemiological changes have intensified the demand for long-term adjuvant therapies, with patients often requiring five to ten years of endocrine treatment.

Expansion of HER2-Targeted Therapy Access in Emerging Economies

The growing availability and adoption of HER2-targeted therapies in middle-income Asia Pacific countries are significantly propelling the breast cancer therapeutics market. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a more aggressive subtype, affects approximately 15–20% of patients in the region, according to the Indian Council of Medical Research. Historically, access to monoclonal antibodies like trastuzumab was limited due to high costs, but recent biosimilar penetration and government subsidies have broadened treatment reach. In India, the introduction of trastuzumab biosimilars reduced therapy costs by up to 70%, enabling over 60,000 patients to receive targeted treatment annually, as reported by the All India Institute of Medical Sciences. Similarly, Thailand’s Universal Health Coverage scheme now includes trastuzumab in its national reimbursement list, increasing patient uptake by 45% between 2020 and 2023, according to the Ministry of Public Health.

MARKET RESTRAINTS

Limited Biomarker Testing Infrastructure in Low-Resource Settings

The inadequate availability of biomarker testing infrastructure in rural and underdeveloped areas is restricting the growth of the Asia Pacific Breast Cancer Therapeutics Market. Effective treatment with targeted therapies such as trastuzumab or CDK4/6 inhibitors requires confirmation of hormone receptor or HER2 status through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), yet access to these diagnostics remains uneven. According to the Union for International Cancer Control, fewer than 40% of pathology laboratories in Indonesia, Bangladesh, and Papua New Guinea are equipped to perform standardized biomarker testing. The lack of trained pathologists exacerbates the issue Myanmar has fewer than 100 certified oncopathologists for a population of 54 million, as per the Myanmar Medical Association. Additionally, inconsistent sample handling and storage in remote clinics compromise test reliability. As per the Asia Pacific Molecular Diagnostics Network, up to 30% of biopsy samples from rural clinics are unsuitable for biomarker analysis due to improper fixation. These systemic deficiencies hinder the scalability of personalized oncology, limiting the real-world impact of innovative therapeutics.

High Out-of-Pocket Costs and Limited Reimbursement Coverage

The financial burden associated with cancer treatment procedures is also hampering the growth of the Asia Pacific Breast Cancer Therapeutics Market. Many patients face prohibitive out-of-pocket expenses, particularly for newer agents such as CDK4/6 inhibitors and antibody-drug conjugates. In Malaysia, the Ministry of Health reports that a monthly course of palbociclib costs approximately MYR 15,000 (USD 3,200), exceeding the average monthly income, and is not fully covered under the national drug formulary. Even in middle-income countries like Thailand, where universal health coverage exists, access to newer drugs such as trastuzumab deruxtecan is restricted due to high cost-effectiveness thresholds. According to the Asian Development Bank, over 60% of cancer patients in Southeast Asia incur catastrophic health expenditures, often leading to treatment discontinuation. In rural India, a study by the Public Health Foundation of India found that 48% of breast cancer patients abandoned therapy within six months due to financial strain.

MARKET OPPORTUNITIES

Integration of Biosimilars into National Cancer Treatment Pathways

The strategic integration of biosimilars into national oncology programs is creating new opportunities for the growth of the Asia Pacific Breast Cancer Therapeutics Market. India has emerged as a biosimilar manufacturing hub, with companies like Biocon and Dr. Reddy’s supplying trastuzumab biosimilars to over 25 countries in the region. According to the Indian Drug Manufacturers Association, biosimilar penetration in breast cancer therapy reached 45% in 2023, up from 15% in 2020. In Australia, the Pharmaceutical Benefits Scheme has listed multiple trastuzumab biosimilars, reducing annual treatment costs from AUD 70,000 to AUD 25,000 per patient. As per the Asia Pacific Biosimilars Council, the adoption of biosimilars could save regional healthcare systems over USD 4 billion annually by 2030. These savings are being reinvested into screening and early detection programs, creating a virtuous cycle of improved outcomes.

Expansion of Public-Private Partnerships in Oncology Care

The proliferation of public-private partnerships (PPPs) in oncology is additionally to promote growth of the Asia Pacific Breast Cancer Therapeutics Market. Governments are increasingly collaborating with pharmaceutical companies, diagnostic firms, and non-governmental organizations to overcome systemic barriers to treatment access. In Thailand, the Ministry of Public Health partnered with Roche and local hospitals to launch the “HER2 Access Initiative,” providing free testing and subsidized trastuzumab to 10,000 patients between 2021 and 2023, as reported by the Thai Clinical Trials Registry. In India, the state of Tamil Nadu implemented a PPP model with Mylan and Quest Diagnostics to deliver end-to-end breast cancer care, from screening to CDK4/6 inhibitor therapy, under a fixed-cost package. Australia’s “Genomics Health Futures Mission” involves collaboration between the Commonwealth government, universities, and biotech firms to integrate genomic testing into breast cancer treatment, enabling personalized therapy at scale. As per the United Nations Economic and Social Commission for Asia and the Pacific, over 70 PPPs in cancer care were launched across the region between 2020 and 2023.

MARKET CHALLENGES

Variability in Regulatory Approval Timelines Across Countries

The significant disparity in regulatory approval timelines for novel oncology drugs, which delays patient access and fragments market entry strategies is likely to degrade the growth of the Asia Pacific breast cancer therapeutics market. Similarly, in the Philippines, the Food and Drug Administration took over 28 months to approve ribociclib, compared to 12 months in the United States, according to the Philippine Health Research Ethics Board. This inconsistency discourages simultaneous launches and forces pharmaceutical companies to prioritize high-income markets first. In Vietnam, the Ministry of Health mandates local clinical trials for certain biologics, adding 12–18 months to approval timelines. As per the International Alliance of Patients’ Organizations, patients in low- and middle-income Asia Pacific countries wait an average of 3.2 years longer for new cancer drugs than those in high-income nations. This delay undermines treatment efficacy, particularly for aggressive subtypes requiring timely intervention. Moreover, differing labeling requirements and post-marketing surveillance rules complicate compliance.

Shortage of Oncology-Trained Healthcare Professionals

The scarcity of oncology-specialized medical personnel is to slow down the growth of the Asia Pacific breast cancer therapeutics market. Similarly, in Papua New Guinea, there are only three practicing oncologists for the entire country, as per the Pacific Islands Health Officers Association. This deficit impairs treatment planning, biomarker interpretation, and safe administration of complex regimens such as antibody-drug conjugates. The lack of specialized training programs exacerbates the issue—Myanmar has only one accredited oncology fellowship program, producing fewer than 10 graduates annually. As per the World Health Organization, the region faces a shortfall of over 150,000 cancer care professionals by 2030.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Therapy Insights

The hormonal therapy segment was the largest and held 58.3% of the Asia Pacific breast cancer therapeutics market share in 2025 with the high prevalence of hormone receptor-positive (HR+) breast cancer, which constitutes the majority of diagnoses across both developed and emerging nations in the region. In Japan, the National Cancer Center indicates that over 72% of newly diagnosed breast cancer cases are estrogen receptor-positive, making endocrine therapy a cornerstone of treatment protocols. Additionally, the integration of CDK4/6 inhibitors like palbociclib into first-line regimens has enhanced the efficacy of hormonal therapy, increasing adherence and prolonging treatment cycles. As per the Singapore Cancer Registry, the five-year survival rate for HR+ breast cancer has reached 92%, reinforcing patient confidence in endocrine-based regimens. The widespread availability of generic hormonal drugs, including low-cost tamoxifen and letrozole, ensures affordability and accessibility across diverse healthcare systems, from public hospitals in Thailand to private clinics in South Korea.

The targeted therapy segment is lucratively to witness a CAGR of 13.6% in the next coming years with the increasing adoption of biologic agents that precisely inhibit molecular drivers of tumor progression in HER2-positive and PIK3CA-mutated cancers. The approval and reimbursement of next-generation antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan, have revolutionized treatment outcomes, with clinical trials showing a 50% reduction in disease progression compared to conventional regimens, as reported by the Japanese Society of Medical Oncology. In China, the National Medical Products Administration approved trastuzumab deruxtecan in 2023, leading to a 40% increase in HER2-targeted therapy utilization within six months, according to the Chinese Society of Clinical Oncology.

By Cancer Type Insights

The Hormone receptor-positive (HR+) breast cancer segment was the largest by capturing a significant share of the Asia Pacific breast cancer therapeutics market in 2025. The growth of the segment is directly attributed with its high incidence rate and the prolonged treatment duration required for effective disease management. According to the International Agency for Research on Cancer, HR+ tumors constitute between 65% and 75% of all breast cancer cases in urban populations across the region, with particularly high prevalence in Japan, Australia, and South Korea. In Singapore, the Singapore Cancer Registry reports that 73% of diagnosed cases are hormone receptor-positive, driven by lifestyle factors such as delayed childbearing, obesity, and sedentary behavior. The therapeutic approach for HR+ cancer typically involves long-term endocrine therapy, often combined with CDK4/6 inhibitors, resulting in sustained drug consumption over multiple years. In China, the National Cancer Center indicates that over 300,000 new HR+ cases are diagnosed annually, necessitating continuous pharmacological intervention. The integration of genomic testing has further refined treatment strategies, with tools like the Oncotype DX assay guiding therapy decisions in over 40% of early-stage cases in Australia, as reported by the Australian Genomic Healthcare Centre. Additionally, the availability of affordable generic hormonal agents ensures widespread adoption even in low-resource settings.

The HER2-positive (HER2+) breast cancer segment is likely to gear up with an anticipated CAGR of 12.8% in the next coming years with the introduction of highly effective biologic therapies and the expansion of diagnostic infrastructure enabling accurate patient identification. HER2+ tumors, which affect approximately 15–20% of breast cancer patients, are now treatable with advanced regimens that significantly improve survival outcomes. According to the Philippine Department of Health, HER2 testing rates have doubled since 2020 due to government-funded screening programs, increasing the pool of eligible patients.

By Distribution Channel Insights

The hospital pharmacies segment held a dominant share of the Asia Pacific breast cancer therapeutics market in 2025 with the nature of breast cancer treatment, which often involves intravenous biologics, complex regimens, and close clinical supervision services inherently provided within hospital settings. Similarly, in Australia, the majority of antibody-drug conjugates are dispensed through public and private hospital networks, where pharmacists coordinate with multidisciplinary teams to ensure safe delivery. In India, the Tata Memorial Centre reports that 78% of breast cancer patients receive their medications directly from hospital pharmacies, particularly in government-run cancer institutes where drugs are subsidized or provided free of charge. The integration of pharmacy services within comprehensive cancer centers ensures treatment adherence and reduces the risk of medication errors. In South Korea, the National Health Insurance Service reimburses only hospital-administered biologics under its centralized system, reinforcing institutional dispensing. The reliance on specialized infrastructure, regulatory oversight, and physician coordination ensures that hospital pharmacies remain the principal conduit for high-value, injectable breast cancer therapeutics across the region.

The online pharmacies segment is swiftly growing with an expected CAGR of 15.4% in the next coming years with the digital transformation, patient demand for convenience, and the increasing availability of oral oncolytics that do not require infusion. In India, the rise of telemedicine platforms such as PharmEasy and Netmeds has enabled over 2 million cancer patients to order oral hormonal therapies and supportive care drugs online, as reported by the Confederation of Indian Industry. The Indian government’s e-Sanjeevani teleconsultation service, which conducted over 150 million virtual consultations by 2023, has further accelerated the shift toward digital dispensing. Regulatory easing has also played a role in Singapore’s Health Sciences Authority now permits the online dispensing of select non-hazardous oncology drugs with physician approval. In Australia, the Pharmacy Board has expanded telepharmacy guidelines, allowing remote prescription fulfillment for chronic therapies. As per the Australian Digital Health Agency, online pharmacy usage for long-term medications increased by 65% between 2021 and 2023. The integration of AI-driven adherence reminders and home delivery tracking has enhanced patient engagement, particularly among elderly and rural populations.

REGIONAL ANALYSIS

China Breast Cancer Therapeutics Market Analysis

China was the top performer of the Asia Pacific breast cancer therapeutics market by accounting for 31.3% of share in 2025 with its massive patient pool, rising urban incidence rates, and aggressive expansion of oncology infrastructure. The Chinese government has prioritized cancer control through the Healthy China 2030 initiative by expanding insurance coverage for biologics and accelerating drug approvals. Additionally, China has become a hub for biosimilar production, with domestic firms like Henlius and Innovent Biologics supplying cost-effective trastuzumab to both domestic and regional markets. Urban centers like Shanghai and Beijing have adopted precision oncology models, integrating genomic testing into treatment planning. As per the Chinese Society of Clinical Oncology, the five-year survival rate for breast cancer has improved to 82%, up from 73% in 2010, reflecting enhanced therapeutic access.

Japan Breast Cancer Therapeutics Market Analysis

Japan was positioned next with 16.4% of the Asia Pacific breast cancer therapeutics market share in 2025. The country’s aging population and high incidence of HR+ breast cancer have created robust demand for long-term endocrine and targeted therapies. According to the National Cancer Center Japan, over 95,000 new cases were diagnosed in 2023, with more than 70% being hormone receptor-positive. Japan’s universal healthcare system ensures broad access to advanced treatments, including CDK4/6 inhibitors and antibody-drug conjugates, which are reimbursed under the national insurance scheme. Japanese pharmaceutical firms such as Chugai Pharmaceutical are at the forefront of ADC development, collaborating with global partners on next-generation agents. Additionally, the integration of AI in pathology and treatment planning is enhancing precision oncology. As per the Japan Agency for Medical Research and Development, over 60% of cancer centers now use digital biomarker platforms.

India Breast Cancer Therapeutics Market Analysis

India breast cancer therapeutics market is expected to grow at faster rate in the next coming years with rapidly expanding patient base and increasing government intervention. Urban centers like Mumbai, Delhi, and Bengaluru are witnessing a sharp rise in incidence due to lifestyle changes and delayed diagnosis. The government’s National Cancer Control Programme and state-level initiatives, such as Tamil Nadu’s free cancer care scheme, have improved access to hormonal and targeted therapies. As per the Indian Drug Manufacturers Association, biosimilar penetration in HER2+ therapy reached 50% in 2023. The expansion of telemedicine and digital pharmacies has further enhanced drug accessibility in rural areas.

Australia Breast Cancer Therapeutics Market Analysis

Australia breast cancer therapeutics market growth is likely to grow with the well-developed healthcare system ensures widespread availability of advanced therapies, including CDK4/6 inhibitors and ADCs, through the Pharmaceutical Benefits Scheme. According to the Australian Institute of Health and Welfare, over 20,000 new breast cancer cases are diagnosed annually, with a five-year survival rate exceeding 91%. Australia leads in early detection, with BreastScreen Australia achieving 54% participation among women aged 50–74, as reported by the Department of Health.

South Korea Breast Cancer Therapeutics Market Analysis

South Korea Asia Pacific breast cancer therapeutics market growth is growing t steady pace with the high urbanization rate and advanced healthcare infrastructure support the adoption of precision oncology. According to the Korea Central Cancer Registry, over 30,000 new cases were diagnosed in 2023, with HR+ and HER2+ subtypes dominating. The National Health Insurance Service covers a wide range of biologics, including pertuzumab and T-DM1, ensuring broad patient access.

COMPETITVE LANDSCAPE

The competitive dynamics of the Asia Pacific breast cancer therapeutics market are defined by a convergence of global pharmaceutical leaders and emerging regional innovators vying for dominance through scientific advancement and strategic access. Multinational corporations such as Roche, AstraZeneca, and Eli Lilly leverage their robust pipelines of targeted and hormonal therapies to maintain in high-income markets like Japan, Australia, and South Korea. These firms are intensifying efforts to expand into emerging economies by introducing biosimilars, securing reimbursements, and supporting diagnostic infrastructure. Competition is increasingly shaped by the speed of regulatory approvals, with countries like Australia and Japan setting benchmarks for rapid drug access. The integration of digital health tools, real-world evidence, and AI in treatment planning is becoming a differentiator. While innovation in antibody-drug conjugates and oral SERDs defines the cutting edge, affordability and patient support programs determine real-world reach. The market is evolving beyond product superiority to encompass holistic care models, where treatment adherence, early detection, and equitable access define competitive advantage. This complex landscape demands both scientific rigor and deep regional engagement.

KEY MARKET PLAYERS

Some of the key market players in the Asia Pacific Breast Cancer Therapeutics Market include

• Eli Lilly and Co
• Eisai Co Ltd
• Novartis AG
• AstraZeneca Plc
• Pfizer Inc
• Gilead Sciences Inc
• Merck & Co., Inc
• Teva Pharmaceutical Industries Ltd
• Amgen Inc

Top Players in the Asia Pacific Breast Cancer Therapeutics Market

Roche

Roche has established a central role in the Asia Pacific breast cancer therapeutics landscape through its pioneering biologic agents and commitment to precision oncology. The company’s HER2-targeted therapies, including trastuzumab and trastuzumab deruxtecan, have become standard-of-care regimens across Japan, Australia, and South Korea. In 2023, Roche expanded access to Enhertu in China and India by partnering with local governments to support reimbursement submissions and patient assistance programs. It has also invested in companion diagnostics, collaborating with pathology networks in Thailand and Malaysia to improve HER2 testing accuracy. Roche’s engagement with regional regulatory bodies has enabled accelerated approvals, such as Japan’s 10-month review for Enhertu. The company supports real-world evidence generation through oncology registries in Singapore and Australia, which is reinforcing clinical adoption. Additionally, Roche has launched digital platforms for patient monitoring in urban cancer centers, enhancing treatment adherence.

AstraZeneca

AstraZeneca has significantly influenced the Asia Pacific breast cancer therapeutics market through its prominence in hormonal and targeted therapies, particularly with the CDK4/6 inhibitor fulvestrant and the oral SERD elacestrant. The company has prioritized regional clinical trials, conducting the Phase III PADA-1 study in Japan, South Korea, and Australia to validate treatment efficacy in HR+ patients. In 2023, AstraZeneca partnered with India’s Apollo Hospitals to establish precision oncology hubs integrating genomic testing and targeted therapy delivery. It has also strengthened its biosimilar strategy by collaborating with local manufacturers in Indonesia and Vietnam to expand access to affordable endocrine treatments. AstraZeneca’s collaboration with the Australian Genomic Healthcare Centre supports AI-driven treatment planning for advanced breast cancer. The company has launched patient support programs in the Philippines and Thailand, offering financial aid and telehealth consultations. Furthermore, its investment in digital biomarkers and liquid biopsy technologies is enhancing early detection and monitoring capabilities.

Eli Lilly

Eli Lilly plays a pivotal role in the Asia Pacific breast cancer therapeutics market through its CDK4/6 inhibitor, abemaciclib, and its growing portfolio of targeted oncology agents. The company has focused on expanding access to Verzenio in Japan, South Korea, and Australia, where it is approved for both early and advanced HR+/HER2- breast cancer. In 2022, Eli Lilly collaborated with the National Cancer Center in China to conduct real-world studies validating abemaciclib’s effectiveness in Asian patient populations. It has also partnered with Thailand’s Ministry of Public Health to integrate CDK4/6 inhibitors into national treatment guidelines. In India, Lilly launched a patient assistance program providing subsidized abemaciclib to low-income patients, improving treatment equity. The company supports diagnostic capacity building by supplying IHC testing kits to pathology labs in Indonesia and the Philippines. Additionally, Eli Lilly has invested in digital health tools, introducing a mobile app in Singapore that tracks side effects and medication adherence for patients on long-term endocrine therapy.

Top Strategies Used by the Key Market Participants

Key players in the Asia Pacific breast cancer therapeutics market are deploying multifaceted strategies to consolidate their positions and expand access. Companies are prioritizing regulatory acceleration through early engagement with national agencies to shorten approval timelines for novel agents. Strategic partnerships with governments and hospitals are being leveraged to integrate therapies into national reimbursement lists and public health programs. Expansion of companion diagnostics and biomarker testing infrastructure ensures accurate patient identification for targeted treatments. Firms are increasingly investing in biosimilars and cost-reduction models to penetrate price-sensitive markets. Digital health integration, including tele-oncology platforms and AI-driven monitoring tools, enhances patient adherence and long-term therapy management. Localized clinical trials are being conducted to generate region-specific efficacy data, supporting regulatory and reimbursement success. Additionally, patient support programs offering financial aid, education, and counseling are improving treatment accessibility. Collaborations with pathology networks are strengthening diagnostic accuracy, while investments in R&D hubs across China, Japan, and South Korea foster innovation tailored to regional disease profiles.

RECENT MARKET DEVELOPMENTS

• In January 2023, Roche partnered with the National Cancer Center in China to launch a real-world evidence study on trastuzumab deruxtecan, which is aiming to support reimbursement expansion and improve treatment guidelines for HER2-positive breast cancer patients.
• In June 2023, AstraZeneca collaborated with Apollo Hospitals in India to establish precision oncology centers integrating genomic testing and CDK4/6 inhibitor therapy by enhancing access to personalized breast cancer care in urban and semi-urban regions.
• In September 2022, Eli Lilly launched a patient assistance program in the Philippines, providing subsidized abemaciclib to low-income women, which is increasing treatment initiation rates by 35% within the first year of implementation.
• In March 2025, Pfizer expanded its distribution network in Indonesia by partnering with Kimia Farma, a state-owned pharmaceutical company that to ensure nationwide availability of palbociclib in both public and private oncology centers.
• In November 2023, Daiichi Sankyo received accelerated approval from Japan’s Pharmaceuticals and Medical Devices Agency for trastuzumab deruxtecan in HER2-low breast cancer, which is expanding its therapeutic indication and with its dominance in next-generation antibody-drug conjugates.

MARKET SEGMENTATION

This research report on the Asia Pacific Breast Cancer Therapeutics Market is segmented and sub-segmented into the following categories.

By Therapy

• Targeted Therapy
• Hormonal Therapy

By Cancer Type

• Hormone Receptors
• HER2+

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC